Clinical Trials
15 trialsNCT03194893 2026-05-20
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03050268 2026-04-23
SJFAMILY
St. Jude Children's Research Hospital
Recruiting
NCT05142189 2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1 Recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT01793168 2025-05-29
CoRDS
Sanford Health
Recruiting
NCT06523582 2024-07-26
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Universidad Nacional Autonoma de Mexico
Recruiting
NCT00390325 2024-02-06
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03780517 2023-10-30
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
Boston Pharmaceuticals
Phase 1 Completed
NCT06081270 2023-10-13
MUT-ONC
University of Milano Bicocca
Unknown
NCT00514046 2020-12-22
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03154086 2019-08-09
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
GlaxoSmithKline
Phase 1 Completed
NCT01424878 2018-04-05
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
National Institutes of Health Clinical Center (CC)
Completed
NCT02831179 2017-09-28
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT00325104 2017-07-02
Cinacalcet to Treat Familial Primary Hyperparathyroidism
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT02727283 2017-05-08
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers
GlaxoSmithKline
Phase 1 Completed